CN103698531B - Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途 - Google Patents
Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途 Download PDFInfo
- Publication number
- CN103698531B CN103698531B CN201310607381.5A CN201310607381A CN103698531B CN 103698531 B CN103698531 B CN 103698531B CN 201310607381 A CN201310607381 A CN 201310607381A CN 103698531 B CN103698531 B CN 103698531B
- Authority
- CN
- China
- Prior art keywords
- antibody
- rv1812c
- protein
- seq
- active tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101100374139 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv1812c gene Proteins 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 18
- 230000000694 effects Effects 0.000 title abstract description 6
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 63
- 208000036981 active tuberculosis Diseases 0.000 claims abstract description 54
- 238000003745 diagnosis Methods 0.000 claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 238000012360 testing method Methods 0.000 claims abstract description 20
- 210000002966 serum Anatomy 0.000 claims abstract description 12
- 238000013461 design Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 29
- 238000001514 detection method Methods 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 238000004458 analytical method Methods 0.000 abstract description 2
- 125000000539 amino acid group Chemical group 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 13
- 230000008034 disappearance Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229910052709 silver Inorganic materials 0.000 description 6
- 239000004332 silver Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical class CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310607381.5A CN103698531B (zh) | 2013-11-25 | 2013-11-25 | Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310607381.5A CN103698531B (zh) | 2013-11-25 | 2013-11-25 | Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103698531A CN103698531A (zh) | 2014-04-02 |
CN103698531B true CN103698531B (zh) | 2015-10-14 |
Family
ID=50360130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310607381.5A Active CN103698531B (zh) | 2013-11-25 | 2013-11-25 | Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103698531B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108267588B (zh) * | 2016-12-30 | 2020-10-23 | 首都医科大学附属北京胸科医院 | 结核分枝杆菌蛋白在制备诊断结核潜伏感染者和/或活动性肺结核产品中的用途 |
CN111157745A (zh) * | 2020-01-17 | 2020-05-15 | 上海交通大学 | 人snrpa蛋白在肺癌复发或转移监测中的用途 |
CN114152746A (zh) * | 2021-08-27 | 2022-03-08 | 江西省胸科医院 | Rv1860蛋白、RV3881c蛋白、Rv2031c蛋白和Rv3803c蛋白在诊断活动性肺结核感染中的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080171345A1 (en) * | 2006-08-10 | 2008-07-17 | Colorado State University Research Foundation | Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens |
CN101687027A (zh) * | 2007-04-04 | 2010-03-31 | 传染性疾病研究院 | 包含结核分枝杆菌多肽及其融合的免疫原性组合物 |
WO2012057904A1 (en) * | 2010-10-27 | 2012-05-03 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
-
2013
- 2013-11-25 CN CN201310607381.5A patent/CN103698531B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080171345A1 (en) * | 2006-08-10 | 2008-07-17 | Colorado State University Research Foundation | Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens |
CN101687027A (zh) * | 2007-04-04 | 2010-03-31 | 传染性疾病研究院 | 包含结核分枝杆菌多肽及其融合的免疫原性组合物 |
WO2012057904A1 (en) * | 2010-10-27 | 2012-05-03 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
Non-Patent Citations (4)
Title |
---|
Dynamic antibody responses to the Mycobacterium tuberculosis proteome;Shajo Kunnath-Velayudhan et al;《PNAS》;20100817;第107卷(第33期);14703-14708 * |
Identification of Mycobacterium tuberculosis Antigens of High Serodiagnostic Value;Gregory C. Ireton et al;《CLINICAL AND VACCINE IMMUNOLOGY》;20101031;第17卷(第10期);1539-1547 * |
Plasma Antibody Profiles as Diagnostic Biomarkers for Tuberculosis;Imran H. Khan et al;《CLINICAL AND VACCINE IMMUNOLOGY》;20111231;第18卷(第12期);2148-2153 * |
Progress on the Biomarkers for Tuberculosis Diagnosis;Tiwei Fu et al;《Critical Reviews in Eukaryotic Gene Expression》;20111231;第21卷(第4期);379-391 * |
Also Published As
Publication number | Publication date |
---|---|
CN103698531A (zh) | 2014-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103698511B (zh) | 结核分支杆菌蛋白在制备诊断潜伏性肺结核感染的产品中的用途 | |
CN103698512B (zh) | 结核分支杆菌蛋白在制备诊断潜伏性肺结核感染的产品中的用途 | |
Green et al. | What tests could potentially be used for the screening, diagnosis and monitoring of COVID-19 and what are their advantages and disadvantages | |
Nielsen et al. | Maximum-likelihood estimation of sensitivity and specificity of ELISAs and faecal culture for diagnosis of paratuberculosis | |
Ten Hove et al. | Detection of diarrhoea‐causing protozoa in general practice patients in The Netherlands by multiplex real‐time PCR | |
Muma et al. | Evaluation of three serological tests for brucellosis in naturally infected cattle using latent class analysis | |
CN104020297B (zh) | 用于结核分枝杆菌感染检测及临床治疗效果监测的试剂盒及其用途 | |
Agapova et al. | Detection of low-concentration host mRNA transcripts in Malawian children at risk for environmental enteropathy | |
ATE447713T1 (de) | S100-proteine und -autoantikörper als serummarker für krebs | |
CN103698531B (zh) | Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途 | |
CN103760345B (zh) | 一种利用外周血检测结核分枝杆菌感染的试剂盒及其应用 | |
CN103954754A (zh) | 一种活动性肺结核的免疫诊断试剂盒 | |
CN103698530B (zh) | 结核分支杆菌蛋白在制备诊断活动性肺结核的产品中的用途 | |
CN103675293B (zh) | Rv3872、Rv0164和/或Rv1926c蛋白在制备诊断活动性肺结核的产品中的用途 | |
CN101738474B (zh) | 一种巨细胞病毒、风疹病毒联合检测试剂检测卡 | |
CN103675292B (zh) | Rv0174、Rv1729c和/或Rv3835蛋白在制备诊断活动性肺结核的产品中的用途 | |
CN105622735B (zh) | 一组结核分枝杆菌蛋白及其编码基因与应用 | |
Neesgaard et al. | Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail | |
CN107202882A (zh) | Rv0440蛋白在诊断潜伏性/活动性肺结核中的用途 | |
CN105671188A (zh) | 用于诊断结核分枝杆菌感染的分子标志物、引物组及应用 | |
CN107202894B (zh) | Rv1078蛋白在诊断潜伏性/活动性肺结核中的用途 | |
CN108504736A (zh) | 检测orm1基因表达量的系统在诊断结核病中的应用 | |
Johnson | Screening for gastrointestinal and pancreatic diseases | |
Zahoor et al. | The sensitivity comparison of immunodiagnostic assays for diagnosing dengue fever | |
KR102368216B1 (ko) | 엘라이자 부스팅 검사법을 이용한 소 결핵병 잠복 감염우의 검출방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160111 Address after: 510663, building 1303, building C2, 182, science Avenue, Science Town, Guangzhou hi tech Industrial Development Zone, Guangdong, China Patentee after: GUANGZHOU BCBIO BIOTECHNOLOGY CO.,LTD. Address before: 1 No. 528000 Guangdong city of Foshan province Foshan City Hing Road Patentee before: TB Healthcare Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231211 Address after: 528000 Foshan, Guangdong, Foshan, Chancheng, No. 70 Gu Xin Road, Foshan science and Technology Industrial Park C high tech Zone 101, 102, 108, 406, 407 Patentee after: GUANGDONG SIGNATURE BIOTECHNOLOGY CO.,LTD. Address before: Unit 1303, Building C2, Innovation Building, No. 182 Science Avenue, Science City, Guangzhou High tech Industrial Development Zone, Guangdong Province, 510663 Patentee before: GUANGZHOU BCBIO BIOTECHNOLOGY CO.,LTD. |